The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for women with locally advanced cervical cancer.
 
Henrique Helber
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo; Gilead Sciences
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences
 
Fernando Maluf
Honoraria - Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS Brazil; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS Brazil; ipsen; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Bayer Schering Pharma; Merck Sharp & Dohme
 
BRAVA Researchers Group
No Relationships to Disclose